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skin disease). We also proposed a limited set of recom-
mendations for a sequential biologic treatment algorithm 
for patients with PsA who failed the first anti-TNF therapy, 
based on the available literature data. There is good evi-
dence that many of the biologic treatments initially tested 
in psoriasis are also effective in PsA. Further research into 
both prognostic biomarkers and patient stratification is 
required to allow clinicians the possibility to make better 
use of the various biologic treatment options available. This 
review showed that there are many potentially new treat-
ments that are not included in the current guidelines that 
can be used for selected categories of patients based on 
their disease phenotype, clinician experience and access to 
new biologic therapies.
Keywords Psoriatic arthritis · Psoriasis · Biologic 
treatments · Small molecule inhibitors · Level of evidence 
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Introduction
Psoriatic arthritis (PsA) is a heterogeneous disease, which 
shares characteristic clinical features (sacroiliitis, spon-
dylitis, enthesitis, psoriasis, uveitis), genetic markers and 
positive family history with the larger group of seronega-
tive spondyloarthropathies. The clinical presentation can 
also be undistinguishable from that of rheumatoid arthritis 
(RA), especially in patients who have PsA with peripheral 
involvement. The diverse clinical picture of PsA suggests 
the need to identify suitable therapies to address different 
combinations of clinical manifestations [1]. Patients will 
experience a decreased quality of life as a consequence of 
pain, functional impairment, cosmetic implications of skin 
and nail lesions, and (in some cases) because of side effects 
Abstract The diverse clinical picture of PsA suggests the 
need to identify suitable therapies to address the different 
combinations of clinical manifestations. This review aimed 
to classify the available biologic agents and new small mol-
ecule inhibitors (licensed and nonlicensed) based on their 
proven efficacy in treating different clinical manifestations 
associated with psoriasis and PsA. This review presents 
the level of evidence of efficacy of different biologic treat-
ments and small molecule inhibitors for certain clinical fea-
tures of treatment of PsA and psoriasis, which was graded 
in categories I–IV. The literature searches were performed 
on the following classes of biologic agents and small mole-
cules: TNF inhibitors (adalimumab, etanercept, infliximab, 
golimumab, certolizumab), anti-IL12/IL23 (ustekinumab), 
anti-IL17 (secukinumab, brodalumab, ixekizumab), anti-
IL6 (tocilizumab), T cell modulators (alefacept, efali-
zumab, abatacept, itolizumab), B cell depletion therapy 
(rituximab), phosphodiesterase 4 inhibitor (apremilast) and 
Janus kinase inhibitor (tofacitinib). A comprehensive table 
including 17 different biologic agents and small molecule 
inhibitors previously tested in psoriasis and PsA was gen-
erated, including the level of evidence of their efficacy for 
each of the clinical features included in our review (axial 
and peripheral arthritis, enthesitis, dactylitis, and nail and 
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to medication. The aspect of functional preservation, pre-
vention of irreversible damage and minimisation of risk of 
co-morbidities are long-term goals for modern therapy in 
PsA [2].
Tailoring the available treatment options according to 
the disease phenotype is needed to ensure the use of a mini-
mal combination of drugs for a maximal therapeutic effect. 
Conventional treatments for PsA have limited efficacy for 
nail disease, enthesitis or axial involvement, and some are 
unable to control moderate and severe peripheral joint and 
skin disease [3]. For the first time, the introduction of bio-
logic treatments offered the possibility of controlling mul-
tiple aspects of these diseases using a single drug, mini-
mising the need for additional therapies. At present, the 
overarching principle of choosing a treatment target based 
on a shared decision between rheumatologists and other 
specialists (such as dermatologists, ophthalmologists, gas-
troenterologists) seems more achievable. This is because 
many of the available biologic treatments are used for sev-
eral indications across different specialties.
Here we reviewed the evidence regarding the efficacy of 
biologic agents for psoriasis and PsA treatment. The pur-
pose of this was to generate a comprehensive summary of 
efficacy of biologic treatments for different clinical features 
of patients with PsA and psoriasis, such as axial disease, 




Adalimumab is a human monoclonal antibody with a high 
affinity for TNFα. Adalimumab is licensed for use in adults 
with severe psoriasis and PsA in whom conventional thera-
pies have failed or are not tolerated.
Evidence of its efficacy in treating both psoriasis and 
PsA is available from numerous RCTs. Different outcome 
measures were improved in the treatment arms, such as 
Psoriasis Area and Severity Index (PASI75) [4], Ameri-
can College of Rheumatology (ACR) responses and PsA 
Response Criteria (PsARC), together with Health Assess-
ment Questionnaires (HAQ), Health Assessment Question-
naire Disability Index (HAQ-DI), Short form-36 health 
survey (SF-36), Dermatology Life Quality Index (DLQI) 
score, Mental Component Summary Score (MCSS) and 
Functional Assessment of Chronic Illness Therapy (FACIT) 
fatigue scale [5–8]. Radiographic progression as measured 
by the modified total Sharp score at weeks 24 and 48 was 
lower in those treated with adalimumab irrespective of 
whether they were receiving methotrexate (MTX) at base-
line [5, 8].
Adalimumab has also demonstrated its superiority 
when compared to conventional therapies, such as metho-
trexate and cyclosporine [9, 10]. In addition, combination 
of DMARDs and adalimumab also showed superiority to 
monotherapy [10].
Adalimumab has been compared directly and indirectly 
with other drugs in the TNF inhibitor group (infliximab, 
etanercept, adalimumab and golimumab) in patients with 
PsA [11–13]. All treatments have demonstrated similar out-
comes and safety profiles. There is also evidence of addi-
tional benefit when switching from one anti-TNF drug to 
another [14, 15].
The clinicians’ choice for a biologic therapy in a par-
ticular patient may be guided by the drug ability to tackle 
specific manifestations of these diseases, such as axial dis-
ease, dactylitis, enthesitis and nail disease. Adalimumab is 
effective for the treatment of dactylitis and enthesitis [16]. 
One RCT [17] and three observational studies have shown 
effectiveness of adalimumab in nail disease as assessed by 
Nail Psoriasis Severity Index (NAPSI) [18–20]. A recent 
publication by the medical board of the National Psoriasis 
Foundation has recommended the use of adalimumab in 
patients with nail disease alone, skin and nail disease or for 
patients with a combination of nail, skin and joint disease 
[21]. Adalimumab was ranked with the “highest enthusi-
asm” compared to all other drugs recommended for nail 
psoriasis.
Adalimumab showed improvement of axial disease in 
patients with ankylosing spondylitis (AS), regardless of 
concomitant presence of psoriasis [22]. In summary, adali-
mumab has shown clear benefits in joint and skin disease. 
Studies have shown a clear reduction in disability and 
improved quality of life. Adalimumab may also be the drug 
of choice for patients with dactylitis, enthesitis and nail dis-
ease. It may also be of use in patients in whom MTX is 
ineffective, or other TNF inhibitors have failed, or in com-
bination with cyclosporine [23].
Etanercept is a fusion protein consisting of the p75 
receptor bound to the Fc region of human immunoglobu-
lin (Ig) G1. It has shown efficacy at 12 weeks for PsARC, 
ACR20, ACR50 and ACR70, PASI75 response criteria and 
improvement in the quality of life, patient rating of pruri-
tus and patient global assessment of psoriasis and physician 
global assessment (PGA) [24–31]. It was also shown to 
inhibit radiographic progression at 12 and 24 months [32, 
33]. A meta-analysis assessing etanercept efficacy in com-
parison with other TNF inhibitors has found a lower rela-
tive risk (RR) for a PASI75 response at week 12, as well as 
a lower RR for PASI75 at 24 weeks than for adalimumab, 
golimumab and infliximab [3].
An observational study looking at patients with PsA with 
axial disease found that 72 % of patients had an improved 
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Bath Ankylosing Spondylitis Disease Activity Index (BAS-
DAI) score whilst taking etanercept [34].
Etanercept is an effective treatment for enthesitis and 
dactylitis, with improvements documented at week 12 and 
week 24 in a multiple-dose study [35]. Similar efficacy has 
also been demonstrated in psoriatic nail treatment [36, 37]. 
Etanercept is currently recommended by the medical board 
of the National Psoriasis Foundation for use in isolated nail 
disease, skin and nail disease, and nail and skin and joint 
disease [21].
In summary, etanercept has proven efficacy in skin and 
joint disease as well as nail disease, dactylitis and enthesi-
tis, and may relieve symptoms of fatigue and depression, 
although, as detailed above, it appears as it is less effective 
than other anti-TNF drugs.
Infliximab is a chimeric monoclonal antibody against 
TNFα, with demonstrated efficacy for treating psoriasis 
[38–41]. In parallel, the drug has also been proven effec-
tive in PsA. The IMPACT RCT demonstrated significant 
ACR20 response at week 16 [39], and additional improve-
ment in quality of life as assessed by HAQ score and SF-36 
health survey at week 14 [42] and week 16 [39]. The effi-
cacy in improving PASI75, PASI90, ACR20, ACR50 and 
ACR70 responses was sustained at week 54, regardless of 
baseline methotrexate use [43]. Infliximab significantly 
inhibited progression of radiographic damage at week 24 
[44].
The EXPRESS RCT found significant improvement 
in nail disease for  % improvement in NAPSI score and 
nail matrix and bed features at weeks 10 and 24 (26.8 
and 57.2 %, respectively, in the infliximab group versus 
−7.7 and −4.1 %, respectively, in the placebo group, both 
p < 0.001). The IMPACT RCT found significant improve-
ment in dactylitis and enthesitis scores at week 16 [39], 
and these were maintained until week 54 in the IMPACT-2 
RCT [43].
Infliximab has demonstrated superiority compared to 
conventional treatments, as assessed by both PsA and pso-
riatic outcome measures [45, 46].
Infliximab has also demonstrated efficacy in psoriasis 
for patients with an inadequate response to etanercept: in 
the PSUNRISE RCT, at week 10, 65.4 % of patients had 
achieved a PGA score of 0 or 1 (indicating clear or almost 
clear disease), and this was sustained until week 26: 61.3 % 
[47].
Certolizumab is a PEGylated Fab’ fragment of a human-
ised TNF inhibitor monoclonal antibody, which has been 
proven beneficial in treating psoriasis [48] and PsA. Cer-
tolizumab has also been associated with preserved effi-
cacy in patients with previous exposure to TNF inhibitors 
[49], sustained effectiveness [50], and additional benefit in 
improving the quality of life [51] and productivity [52]. In 
addition, there was significant inhibition of radiographic 
progression as measured by the modified total Sharp score 
at week 24 [53].
Certolizumab is also effective in treating enthesitis, dac-
tylitis and nail disease associated with PsA and psoriasis, 
showing a significant difference versus placebo regardless 
of the dose [49].
Golimumab is a novel monoclonal antibody against 
TNFα, engineered in a transgenic mice model. The GO-
REVEAL RCT demonstrated significant efficacy for treat-
ing psoriasis and PsA at week 14 as measured by ACR20 
and PASI75 responses, and positive impact on quality of 
life, as reflected by significant improvements in the HAQ 
[54]. Efficacy was maintained at 5 years [55]; however, 
31 % of patients had discontinued treatment after 5 years. 
Golimumab also proved to be effective in treating enthesitis 
at week 24 [54, 56]; however, dactylitis score was only sig-
nificantly decreased with the 100-mg dose of golimumab 
compared to placebo [56]. Golimumab was also effective in 
treating nail disease [54].
T cell modulators
Inhibition of T cell co‑stimulatory MOLECULES
Abatacept is a fusion protein that binds to CD80 and CD86 
and interferes with T cell signalling and activation, produc-
ing a reduction in inflammation. It has shown to be effec-
tive in the treatment of PsA and psoriasis (as assessed by 
ACR20, SF-36, HAQ and PASI scores); in addition, there 
were improvements in joint erosions, osteitis and synovi-
tis [57]. It was noticed that skin response was inconsistent, 
and TNF-naïve patients showed greater responses.
Despite this, abatacept has failed to show efficacy in 
AS in a 24-week open-label study [58]. There have been 
no data to support its use in psoriatic arthritis with axial 
involvement.
Alefacept is a dimeric fusion protein that consists of 
the extracellular CD2-binding portion of the human leu-
cocyte function antigen-3 (LFA-3) linked to the Fc portion 
of human IgG1 which acts as a T cell modulator. Studies 
have shown efficacy at week 12 for PASI75 [59–61] and 
DLQI [62]. When used in combination with methotrex-
ate, the treatment was superior to MTX alone (as assessed 
by ACR20 and PASI50 scores at week 24) [63]. There are 
no data to support its efficacy in axial disease, dactylitis, 
enthesitis or nail disease.
Efalizumab is a recombinant humanised monoclonal 
antibody which binds to the CD11a subunit of LFA-1 and 
acts as an immunosuppressant by inhibiting lymphocyte 
activation and cell migration out of blood vessels into tis-
sues, which was not superior to placebo in treating PsA 
[64], despite being proven effective in treating psoriasis 
[64, 65]. This drug was withdrawn in 2009 in Europe and 
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the USA because of the increased risk of progressive multi-
focal leukoencephalopathy [64].
Itolizumab is the first humanised IgG1 monoclonal anti-
body, which targets selectively CD6, a marker involved in 
co-stimulation, adhesion and maturation of T cells, which 
was tested in psoriasis. The treatment was proven effective 
in improving the PASI75 score in several RCTs of patients 
with psoriasis [66, 67] and was licensed for use in India in 
2013.
Phosphodiesterase 4 inhibitors
Apremilast is a phosphodiesterase 4 inhibitor, which 
increases levels of cAMP, resulting in decreased levels of 
proinflammatory cytokines.
This treatment was shown effective in PsA treatment 
[68]. The PALACE studies, a group of large phase III tri-
als, have demonstrated its efficacy for ACR20 response at 
week 16 [69]. Continuous efficacy was noted for HAQ-DI, 
enthesitis and dactylitis (even if the improvement of the last 
two clinical features did not reach statistical significance 
at week 24). An improvement in skin psoriasis was also 
noted, although this was less significant. Efficacy on axial 
disease was not investigated.
A separate study looking at psoriasis found the treatment 
effective (significant improvements in PASI75, pruritus, 
DLQI and physician global assessment). There was also 
evidence for its role in nail disease treatment [70]. Apre-
milast is currently recommended by the National Psoriasis 
Foundation for skin and nail disease and skin, nail and joint 
disease, but with less enthusiasm and a lower ranking than 
adalimumab and etanercept [21].
Anti‑interleukin biologic agents
IL12/IL23 inhibition
Ustekinumab is a human monoclonal antibody directed 
against the p40 subunit of IL12/IL23, which has shown 
remarkable efficacy in the treatment of psoriasis [71–73], 
with associated sustained efficacy after 3 years of treat-
ment; [74]. Efficacy has also been observed for the treat-
ment of PsA, reflected in significant improvement in 
ACR20 at 12 and 24 weeks [75–77]. There was also sig-
nificant improvement in quality of life, reflected by DLQI 
scores and HAQ-DI response at week 12 [78], together 
with ACR50, ACR70, Disease Activity Score (DAS28-
CRP) responses and PASI75 at week 24 [76, 77]. Com-
bined radiographic analysis of PSUMMIT 1 and 2 RCT 
showed significantly less radiographic progression in the 
active treatment groups [79].
Ustekinumab has proven efficacy in treating psoriatic 
nail disease [80] and for the treatment of enthesitis [76, 
77]. However, whilst the PSUMMIT-1 RCT found that 
ustekinumab was efficacious in treating dactylitis and 
spondylitis reflected in the improvement in BASDAI score 
[76], PSUMMIT-2 did not find any significant difference 
between ustekinumab and placebo [75].
The ACCEPT RCT which compared head-to-head 
ustekinumab with etanercept found greater, but nonsignifi-
cant PASI75 response in the ustekinumab arm (67.5 % for 
the dose of 45 mg and 73.8 % for the dose of 90 mg vs. 
etanercept 56.8 %) [81].
IL17 inhibition
Secukinumab is an IL17A monoclonal antibody, with rec-
ognised efficacy in treating psoriasis. The ERASURE and 
JUNCTURE RCTs showed significant increase in PASI75 
response and Modified-IGA response of 0 or 1 (indicat-
ing clear or almost clear psoriatic disease) versus placebo 
at week 12 [82, 83]. The treatment had also potential 
to improve the response when switched to intravenous 
administration [84]. There may be a role for secukinumab 
in the treatment of PsA, as proven by the FUTURE-1 
[85] FUTURE-2 [86], as well as in treating skin disease 
and extra-articular manifestations (such as dactylitis and 
enthesitis) [85, 86]. Efficacy was observed regardless of use 
of prior TNF inhibitor. FUTURE-1 RCT also demonstrated 
significantly greater inhibition of joint structural damage at 
week 24, with responses maintained at week 52 [87].
Secukinumab may have a greater efficacy than the cur-
rently licensed biologics for psoriasis as proven by the FIX-
TURE RCT, which compared it to etanercept (p < 0.001) 
[82].
Brodalumab is a monoclonal antibody that targets and 
blocks the signalling pathway of interleukin receptors 
(IL17A, IL17F and IL23), which has been proven effec-
tive for psoriasis treatment. A phase 2 dose-ranging RCT 
has demonstrated significant increase in PASI75 response 
at week 12 regardless of dosage; in addition, significantly 
greater PASI90 response was seen in the 140- and 210-mg 
dose versus placebo [88]. The long-term efficacy of broda-
lumab for psoriasis is demonstrated by the sustained skin 
response from week 12 to week 120 [89]. There could be 
a potential role for brodalumab in the treatment of PsA 
as well: a phase 2 RCT showed a significant increase in 
ACR20 response at week 12, and the ACR20 response was 
similar in patients who had or had not received any previ-
ous biologic treatment [90]. This study did show significant 
improvement in the BASDAI score, but was not significant 
for the treatment of enthesitis and dactylitis.
Ixekizumab is a humanised monoclonal antibody against 
IL 17A, which has shown benefits for the treatment of pso-
riasis: in a phase 2 RCT, a significantly increased PASI75, 
PASI90 and PASI100 response was found at week 12, for 
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the 75- and 150-mg dosage [91]. Another phase 2 RCT 
found potential efficacy for scalp psoriasis and nail disease 
improvement at week 12 [92].
IL6 inhibition
Tocilizumab is a monoclonal antibody against IL6, which 
has shown no efficacy in controlling symptoms of AS in 
two short-term RCTs, despite being effective in decreasing 
the CRP levels in the treatment arm [93]. No further studies 
in seronegative spondyloarthropathy were planned.
B cell depletion therapy
Rituximab is a chimeric monoclonal antibody against the 
protein CD20, which is primarily found on the surface of B 
cells. An exploratory open-label study found modest clini-
cal improvement in ACR20 and enthesitis scores, but no 
improvement of PASI scores, dactylitis or BASDAI scores 
[94]. No other trials of Rituximab in PsA were planned.
Small molecule inhibitors
Janus kinase inhibitors
Tofacitinib is an oral inhibitor of Janus kinase, which has 
demonstrated significant benefit for the treatment of pso-
riasis: a phase 2b trial demonstrated a significant PASI75 
response at week 12, regardless of dosage [95, 96]. There 
is no published date for tofacitinib in the treatment of PsA, 
but clinical trials are currently ongoing.
Discussions
There is clear evidence from the literature data that the 
biologic therapeutic armamentarium for psoriasis and PsA 
is rapidly expanding. The majority of biologic treatments 
were first assessed for efficacy in psoriasis. Important 
observations emerged from recent clinical trials proving 
that the new biologic treatments for psoriasis have certain 
advantages when compared to the licensed ones.
Secukinumab and ustekinumab had greater efficacy 
compared to etanercept, as per two head-to-head studies in 
psoriasis. Alefacept showed sustained treatment benefit for 
a drug-free follow-up period of 12 weeks in patients with 
psoriasis (suggesting the possibility of intermittent treat-
ment regimens), and itolizumab was associated with very 
prolonged drug-free remission (up to 5 years) [97].
In terms of treatment opportunities for patients with 
PsA, the new biologics reassuringly showed similar control 
of peripheral joint symptoms (indirect comparison showed 
the following percentages of ACR20 response: usteki-
numab 90 mg, 42 %; secukinumab 300 mg, 54 %; broda-
lumab 280 mg, 64 %; abatacept 10 mg/kg, 48 %; apremi-
last 20 mg daily, 43.5 %, which is comparable to infliximab 
5 mg/kg, 65 %; certolizumab 200 mg e.o.w., 58 %; goli-
mumab 100 mg monthly, 61 %; adalimumab 40 mg e.o.w, 
58 %; and etanercept 25 mg twice weekly, 59 %). Differ-
ent aspects of the disease activity, such as dactylitis and 
enthesitis, were effectively controlled by anti-TNF ther-
apy, and also by ustekinumab and secukinumab. The axial 
involvement also responded to therapy with ustekinumab 
and secukinumab, and the nail involvement, enthesitis 
and dactylitis associated with PsA were all improved with 
treatment with apremilast and sekukinumab (along with 
infliximab, certolizumab, etanercept, adalimumab and 
golimumab).
Optimising therapy for those patients who failed anti-
TNF treatments is one of the main challenges of manag-
ing patients with severe, longstanding PsA. In order to 
determine the efficacy of new biologics in this category of 
patients, different strategies of optimising the doses were 
assessed in clinical trials with secukinumab. The dose 
adjustment (intravenous loading dose and use of the 300-
mg dose monthly) showed the best response in PsA patients 
previously treated with anti-TNF therapy.
Recent data from the NOR-DMARD cohort showed 
that the response to the second anti-TNF, in patients with 
PsA who failed the first anti-TNF, is significantly lower 
[14]; the use of other biologic treatments with different 
mechanisms of action is therefore currently considered a 
better option. In comparison with RA, and in both AS and 
PsA, the retention rates of first anti-TNF treatment and the 
response to the second anti-TNF are higher, although these 
are decreased compared to the first anti-TNF agent [98]. 
Therefore, the switch to the second anti-TNF might there-
fore be recommended in most cases when no other (bio-
logic) treatments are available.
Table 1 includes a summary of biologic treatments and 
their efficacy for different clinical manifestations in PsA 
and psoriasis, using the following level of evidence classifi-
cation (Oxford Centre of Evidence-based Medicine, 2009):
1a  Systematic reviews (with homogeneity) of ran-
domised controlled trials
1b  Individual randomised controlled trials (with 
narrow confidence interval)
1c  “All or none” randomised controlled trials
2a  Systematic reviews (with homogeneity) of cohort 
studies
2b  Individual cohort study or low-quality ran-
domised controlled trials (e.g. <80 % follow-up)
2c  “Outcomes” research; ecological studies
3a  Systematic review (with homogeneity) of 
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case–control studies
3b  Individual case–control study
4  Case series (and poor quality cohort and case–
control studies)
5  Expert opinion without explicit critical appraisal, 
or based on physiology, bench research or “first 
principles”
It is difficult to establish an algorithm for sequential bio-
logic treatment in PsA patients who failed the first biologic 
(usually an anti-TNF drug), due to of lack of evidence of 
efficacy of the majority of new drugs as second-line bio-
logic therapies.
Based on the information available, we can make the 
following recommendations for treatment of PsA patients 
who failed one anti-TNF treatment: ustekinumab can be 
used as second-line biologic in psoriatic and PsA patients 
who failed TNF treatments (level of evidence 1b); sekuki-
numab at higher dose (300 mg monthly) and with addi-
tional IV loading dose is effective in PsA patients who 
failed anti-TNF therapy (level of evidence 1b); and the use 
of a second anti-TNF therapy can be effective in patients 
who failed the first anti-TNF treatment (certolizumab and 
golimumab, level of evidence 1b; infliximab and adali-
mumab and etanercept, level of evidence 2b).
In summary, this review highlighted that the number of 
biologic treatments for PsA and psoriasis increased sig-
nificantly in the recent years and will probably lead in the 
future to the licensing of new therapies. Given the hetero-
geneity of both PsA and psoriasis, the treatments should 
be tailored to individual cases. Further research into both 
prognostic biomarkers and patient stratification is required 
to allow clinicians the possibility to make better use of the 
various biologic treatment options available.
Table 1  Biologic treatment effectiveness in relation to various disease manifestations
* Level of evidence
Treatment Peripheral arthritis Sacroiliitis and 
spinal disease
Enthesitis Dactylitis Nail involvement Skin psoriasis
TNF inhibitors
ADALIMUMAB YES (*1a) YES (*1a) YES (*1a)
ETANERCEPT YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
CERTOLIZUMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
GOLIMUMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
INFLIXIMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a) YES (*1a)
T cell modulators
ABATACEPT YES (*1b) NO (*1b)-study in 
AS
YES (*1b)




NO (*1b) YES (*1a)
Phosphodiesterase 4 Inhibitors
APREMILAST YES (*1a) YES (*1b) YES (*1b) YES (*1b) YES (*1a)
IL inhibition
USTEKINUMAB YES (*1a) YES (*1b) YES (*1b) YES (*1b) YES (*1a)
BRODALUMAB YES (*1b) YES (*1b) NO (*1b) NO (*1b)
IXEKIZUMAB Ongoing study Ongoing study Ongoing study Ongoing study YES (*1a)
SECUKINUMAB YES (*1a) YES (*1a) YES (*1a) YES (*1a)
TOCILIZUMAB YES (*4) NO (*1b) YES (pustular psoria-
sis) (*4)
B cell depletion therapy
RITUXIMAB NO (*1b) YES (*1b) NO (*1b)
Small molecule inhibitors
TOFACITINIB Ongoing studies Under recruitment 
in AS
Ongoing studies Ongoing studies YES (*1a)
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